From 31 centers, 166 patients were entered. Of this intent-to-treat group, 48% responded. With a median follow-up duration of 11.8 months, the projected median time to progression for responders is 13 ...
The "Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2014-2020" report has been added to ResearchAndMarkets.com’s offering. The Global Cancer Monoclonal Antibody Partnering Terms and ...
In 1975, Georges Köhler and César Milstein, biochemists from the Medical Research Council Laboratory of Molecular Biology, published a paper in Nature about a hybridoma technology that enabled the ...
Monoclonal antibodies (mAbs) are highly specific, laboratory-produced antibodies designed to target a single specific epitope or binding site on an antigen. Unlike polyclonal antibodies, which are a ...
Jan Vilcek, M.D., Ph.D., is a professor of microbiology at New York University Langone Medicine Center. Research in his laboratory led to the development of cA2, the first chimeric monoclonal antibody ...
Antibodies are a critical feature of the human adaptive immune response. New immunotherapies require the production of selective and non-autoimmunogenic antibodies. These engineered antibodies can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results